Recursion Pharmaceuticals annual return on equity
2021
2022
2023
2024
2025
Recursion Pharmaceuticals Return on Equity (ROE) Growth & History (RXRX)
Recursion Pharmaceuticals's return on equity was −59.54% for fiscal 2025.
View full Recursion Pharmaceuticals company overviewRecursion Pharmaceuticals annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −59.54% | +2.35 pp |
| 2024 | 2024-12-31 | −61.89% | +7.23 pp |
| 2023 | 2023-12-31 | −69.12% | −22.56 pp |
| 2022 | 2022-12-31 | −46.56% | +64.23 pp |
| 2021 | 2021-12-31 | −110.79% | — |
Recursion Pharmaceuticals quarterly return on equity
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −13.51% | +5.05 pp |
| Q1 2026 | 2026-03-31 | −10.90% | +9.67 pp |
| Q4 2025 | 2025-12-31 | −9.93% | +13.02 pp |
| Q3 2025 | 2025-09-30 | −16.51% | +0.78 pp |
| Q2 2025 | 2025-06-30 | −18.55% | +1.24 pp |
| Q1 2025 | 2025-03-31 | −20.57% | +0.57 pp |
| Q4 2024 | 2024-12-31 | −22.95% | −2.31 pp |
| Q3 2024 | 2024-09-30 | −17.28% | +3.23 pp |
| Q2 2024 | 2024-06-30 | −19.79% | −2.73 pp |
| Q1 2024 | 2024-03-31 | −21.14% | −6.87 pp |
| Q4 2023 | 2023-12-31 | −20.63% | −7.48 pp |
| Q3 2023 | 2023-09-30 | −20.51% | −5.87 pp |
| Q2 2023 | 2023-06-30 | −17.07% | −2.98 pp |
| Q1 2023 | 2023-03-31 | −14.26% | −3.46 pp |
| Q4 2022 | 2022-12-31 | −13.16% | −1.79 pp |
| Q3 2022 | 2022-09-30 | −14.64% | −7.00 pp |
| Q2 2022 | 2022-06-30 | −14.08% | +7.11 pp |
| Q1 2022 | 2022-03-31 | −10.80% | — |
| Q4 2021 | 2021-12-31 | −11.37% | — |
| Q3 2021 | 2021-09-30 | −7.64% | — |
| Q2 2021 | 2021-06-30 | −21.19% | — |
Recursion Pharmaceuticals return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Recursion Pharmaceuticals's return on equity increased from −110.79% to −59.54%, a change of +51.24 percentage points. The latest reported quarter, Q2 2026, shows −13.51%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Recursion Pharmaceuticals source filings ↗